Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...

An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...

Body-weight cycling, sometimes referred to as yo-yo dieting, may be harmful to the kidneys for people with type 1 diabetes, ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...